Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients Academic Article Article uri icon


MeSH Major

  • Enzyme Inhibitors
  • Phlebotomy
  • Piperazines
  • Polycythemia Vera
  • Pyrimidines


  • © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

publication date

  • January 2019



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/cam4.2107

PubMed ID

  • 31173472

Additional Document Info

start page

  • 4089

end page

  • 4092


  • 8


  • 9